治療不応性悪性リンパ腫に対するVP-16, Ifosfamide, Procarbazine, Prednisolone, Bleomycin, Methotrexate (VIPP-BM)併用療法

大西 一功; 堀田 知光; 村手 隆; 井上 千加子; 市川 篤; 二宮 信夫; 後藤 整一; 津下 圭太郎; 内海 真; 名倉 英一; 山田 英雄; 斎藤 英彦; 山雄 久美; 水野 晴光

doi:10.11406/rinketsu.30.289

Salvage Chemotherapy with a Combination of VP-16, Ifosfamide, Procarbazine, Prednisolone, Bleomycin and Methotrexate (VIPP-BM) for Refractory Malignant Lymphoma

Kazunori OHNISHI, Tomomitsu HOTTA, Takashi MURATE, Chikako INOUE, Atsushi ICHIKAWA, Nobuo NINOMIYA, Seiichi GOTO, Keitaro TSUSHITA, Makoto UTSUMI, Ei-ichi NAGURA, Hideo YAMADA, Hidehiko SAITO, Hisami YAMAO, Harumitsu MIZUNO

Author information

Kazunori OHNISHI
First Department of Internal modicine, Nagoya University School of Medicine
Tomomitsu HOTTA
First Department of Internal modicine, Nagoya University School of Medicine
Takashi MURATE
First Department of Internal modicine, Nagoya University School of Medicine
Chikako INOUE
First Department of Internal modicine, Nagoya University School of Medicine
Atsushi ICHIKAWA
First Department of Internal modicine, Nagoya University School of Medicine
Nobuo NINOMIYA
First Department of Internal modicine, Nagoya University School of Medicine
Seiichi GOTO
First Department of Internal modicine, Nagoya University School of Medicine
Keitaro TSUSHITA
First Department of Internal modicine, Nagoya University School of Medicine
Makoto UTSUMI
First Department of Internal modicine, Nagoya University School of Medicine
Ei-ichi NAGURA
First Department of Internal modicine, Nagoya University School of Medicine
Hideo YAMADA
First Department of Internal modicine, Nagoya University School of Medicine
Hidehiko SAITO
First Department of Internal modicine, Nagoya University School of Medicine
Hisami YAMAO
Department of Hematology, Chukyo Hospital
Harumitsu MIZUNO
Department of Hematology, Chukyo Hospital

Keywords: refractory lymphoma, salvage chemotherapy

JOURNAL RESTRICTED ACCESS

1989 Volume 30 Issue 3 Pages 289-296

DOI https://doi.org/10.11406/rinketsu.30.289

Details

Abstract

Twenty patients with refractory malignant lymphoma were treated with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) as salvage chemotherapy. These patients were either resistant to front-line therapy or refractory in their relapses. Two patients (10%) achieved a complete remission and eleven patients (55%) atained a partial remission. An overall response rate was 65%. Major toxicities were myelosuppression, nausea and vomiting, and mucositis. However they were well tolerated. This regimen has been effective in the treatment for the patients with refractory lymphoma.

Corresponding author

Register with J-STAGE for free!